Arbutus Biopharma Corporation
ABUSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. At a $900.8M market cap, Arbutus Biopharma Corporation ranks as a small-cap company within healthcare. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Market Cap
$900.8M
Beta
0.62
P/E (TTM)
5.70
P/E (Fwd)
-27.59
EPS (TTM)
$0.80
EPS (Fwd)
$-0.17
ROE
94.7%
ROA
49.2%
Cash
$95.2M
Total Debt
$3.9M
Free CF
-$90.4M
52W Change
45.7%
Annual Financials
Cash vs Debt
Arbutus Biopharma Corporation holds $95.2M in cash against $3.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$90.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 94.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 49.2% further supports the picture of efficient asset utilization. Revenue has pulled back from $39.0M (2022) to $14.1M (2025), a 64% decline worth watching.
With a beta below 0.7, Arbutus Biopharma Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ABUS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Arbutus Biopharma Corporation's trajectory.